Maher, Toby M. http://orcid.org/0000-0001-7192-9149
Bendstrup, Elisabeth
Dron, Louis
Langley, Jonathan
Smith, Gerald
Khalid, Javaria Mona
Patel, Haridarshan
Kreuter, Michael
Funding for this research was provided by:
Galapagos NV
Article History
Received: 22 April 2021
Accepted: 29 June 2021
First Online: 7 July 2021
Declarations
:
: Not applicable.
: Not applicable.
: TMM, via his institution, has received industry-academic funding from GlaxoSmithKline and UCB, and has received consultancy or speaker fees from Apellis, AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, GlaxoSmithKline, Indalo, Novartis, Pliant, ProMetic, Respivant, Roche, Samumed, and UCB outside the submitted work<i>.</i> EB reports grants and personal fees from Galapagos during the conduct of the study, and from AstraZeneca, Boehringer Ingelheim and Roche outside the submitted work. LD and GS are employees of Cytel, which received funding from Galapagos NV for the current work. JL and JMK are employees of and warrant holders at Galapagos NV. HP is an employee of Immensity Consulting, Inc. which received funding from Galapagos NV for the current work. MK reports grants and personal fees from Galapagos during the conduct of the study, and grants and personal fees from Boehringer Ingelheim and Roche outside the submitted work.